Results 1 to 10 of about 63,889 (276)

Infliximab in the treatment of rheumatoid arthritis

Biologics: Targets & Therapy, 2009
A PerdrigerService de Rhumatologie, CHU de Rennes, Hôpital sud, FranceAbstract: Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis (RA).
A Perdriger
doaj   +2 more sources

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update

Clinical and Experimental Gastroenterology, 2009
Garrett Lawlor, Alan C MossBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: Infliximab is a monoclonal antibody against tumor necrosis factor (TNF) which has become an established therapy for Crohn’s ...
Garrett Lawlor, Alan C Moss
doaj   +1 more source

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

Open Access Rheumatology: Research and Reviews, 2017
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O'Sullivan M, Curran AM, Carey JJ   +8 more
doaj   +1 more source

A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab early colectomy

Therapeutic Advances in Chronic Disease, 2019
Background: Early intervention for acute severe ulcerative colitis (ASUC) improves outcomes. Outcomes and healthcare costs for an infliximab-first and colectomy-first approach were compared.
Abhinav Vasudevan, Asiri Arachchi, Cian Scanlon, Jarrod Greenhalgh, Daniel R. Van Langenberg   +4 more
doaj   +1 more source

Effect of infliximab dose increase in rheumatoid arthritis at different trough concentrations: a cohort study in clinical practice conditions

Frontiers in Medicine, 2015
BackgroundEvidence supporting treatment intensification in rheumatoid arthritis is limited and controversial. We explored outcomes of infliximab dose increases and accounted for pre-existing trough levels in patients with active rheumatoid arthritis (RA).
Chamaida ePlasencia, Teresa eJurado, Alejandro eVillalba, Diana ePeitedado, Maria Teresa López Casla, Laura eNuño, María Gema Bonilla, Ana eMartínez-Feito, Emilio eMartín-Mola, Dora ePascual-Salcedo, Alejandro eBalsa   +10 more
doaj   +1 more source

Cystoid Macular Edema: Possible Complication of Infliximab Therapy in Behçet’s Disease

Case Reports in Ophthalmology, 2010
Aim: Infliximab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, has been reported to be effective in refractory uveoretinitis in Behçet’s disease.
Junko Ikewaki, Hirofumi Kono, Kei Shinoda, Toshiaki Kubota, Kazuo Nakatsuka   +4 more
doaj   +1 more source

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.

PLoS ONE
BackgroundThe Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV ...
Nimer S Alkhatib, Abdulaali R Almutairi, Majid Almadi, Shiraz Halloush, Yazed Sulaiman H Al-Ruthia, Omar Rashdan, Samah Al-Shatnawi, Nahla A Azzam, Mahmoud H Mosli, Amal M Badawoud, Majed S Al Yami, Abdulaziz Alhossan, Ibtisam AlHarbi   +12 more
doaj   +1 more source

Clinical experience with infliximab administration in patients with rheumatoid arthritis by Russian register data

Терапевтический архив, 2009
Aim. To analyse the data on infliximab administration (efficacy, tolerance, toxicity) in patients with rheumatoid arthritis (RA) in Russia by clinical evidence provided by the multicenter observation trial. Material and methods. The register included 297
Galina Viktorovna Lukina, Yakov Aleksandrovich Sigidin, Evgeniy L'vovich Nasonov, G V Lukina, Ya A Sigidin, E L Nasonov   +5 more
doaj  

Comparative outcomes of advanced medical rescue therapies in steroid-refractory acute severe ulcerative colitis: a systematic review and network meta-analysis

Frontiers in Gastroenterology
BackgroundSteroid-refractory acute severe ulcerative colitis is a medical emergency associated with a substantial risk of colectomy. Although infliximab and calcineurin inhibitors are established rescue treatments, comparative evidence regarding ...
Mohamad Yousef Alabdallat, Omar Al Ta’ani, Tarek Bakain, Ahmad Al-Dwairy, Mohammad Ghannam, Abdulrahman Atasi, Fares Mashal, Khaled Moghib, Nader Bakheet, Javed G. Jagroo, Rohan Hehr, Ahmed Salem, Derrick Cheung   +12 more
doaj   +1 more source

Infliximab treatment for steroid-refractory acute graft-versus-host disease

Haematologica, 2004
BACKGROUND AND OBJECTIVES: Tumor necrosis factor a is one of the principal cytokines involved in the pathogenesis of acute graft-versus-host-disease (GVHD). Infliximab is an antibody to this cytokine.
F Patriarca, A Sperotto, D Damiani, G Morreale, F Bonifazi, A Olivieri, F Ciceri, G Milone, S Cesaro, G Bandini, G Dini, P Corradini, R Fanin   +12 more
doaj